Christopher A. Klebanoff, M.D.
Cited by
Cited by
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni, SE Finkelstein, CA Klebanoff, PA Antony, DC Palmer, ...
The Journal of experimental medicine 202 (7), 907-912, 2005
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
L Gattinoni, CA Klebanoff, DC Palmer, C Wrzesinski, K Kerstann, Z Yu, ...
The Journal of clinical investigation 115 (6), 1616-1626, 2005
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
CA Klebanoff, L Gattinoni, P Torabi-Parizi, K Kerstann, AR Cardones, ...
Proceedings of the national academy of sciences 102 (27), 9571-9576, 2005
Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells
WW Overwijk, MR Theoret, SE Finkelstein, DR Surman, LA De Jong, ...
The Journal of experimental medicine 198 (4), 569-580, 2003
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
PA Antony, CA Piccirillo, A Akpinarli, SE Finkelstein, PJ Speiss, ...
The Journal of Immunology 174 (5), 2591-2601, 2005
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
M Sukumar, J Liu, Y Ji, M Subramanian, JG Crompton, Z Yu, ...
The Journal of clinical investigation 123 (10), 4479-4488, 2013
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
CA Klebanoff, SE Finkelstein, DR Surman, MK Lichtman, L Gattinoni, ...
Proceedings of the National Academy of Sciences 101 (7), 1969-1974, 2004
CD8+ T‐cell memory in tumor immunology and immunotherapy
CA Klebanoff, L Gattinoni, NP Restifo
Immunological reviews 211 (1), 214-224, 2006
Paths to stemness: building the ultimate antitumour T cell
L Gattinoni, CA Klebanoff, NP Restifo
Nature Reviews Cancer 12 (10), 671-684, 2012
TOX is a critical regulator of tumour-specific T cell differentiation
AC Scott, F DŁndar, P Zumbo, SS Chandran, CA Klebanoff, M Shakiba, ...
Nature 571 (7764), 270-274, 2019
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
CA Klebanoff, HT Khong, PA Antony, DC Palmer, NP Restifo
Trends in immunology 26 (2), 111-117, 2005
Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels
JN Kochenderfer, RPT Somerville, T Lu, V Shi, A Bot, J Rossi, A Xue, ...
Journal of clinical oncology 35 (16), 1803, 2017
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
CS Hinrichs, R Spolski, CM Paulos, L Gattinoni, KW Kerstann, DC Palmer, ...
Blood, The Journal of the American Society of Hematology 111 (11), 5326-5333, 2008
Ionic immune suppression within the tumour microenvironment limits T cell effector function
R Eil, SK Vodnala, D Clever, CA Klebanoff, M Sukumar, JH Pan, ...
Nature 537 (7621), 539-543, 2016
Th17 cells are long lived and retain a stem cell-like molecular signature
P Muranski, ZA Borman, SP Kerkar, CA Klebanoff, Y Ji, L Sanchez-Perez, ...
Immunity 35 (6), 972-985, 2011
BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis
R Roychoudhuri, K Hirahara, K Mousavi, D Clever, CA Klebanoff, ...
Nature 498 (7455), 506-510, 2013
Therapeutic cancer vaccines: are we there yet?
CA Klebanoff, N Acquavella, Z Yu, NP Restifo
Immunological reviews 239 (1), 27-44, 2011
Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma
SL Goff, ME Dudley, DE Citrin, RP Somerville, JR Wunderlich, ...
Journal of Clinical Oncology 34 (20), 2389, 2016
Prospects for gene-engineered T cell immunotherapy for solid cancers
CA Klebanoff, SA Rosenberg, NP Restifo
Nature medicine 22 (1), 26-36, 2016
The system can't perform the operation now. Try again later.
Articles 1–20